Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: To all: I just received the letter addresed to David Pohl from Ronran.

Thanks for the response. It's not that I'm worked up about it, after seeing what's transpired, it just drives me for clarification and understanding of our directors moves after the fact. Pohl's creating value for the shareholder just gets more diluted as time goes on as the story unfolds. Or as it's previously been said, everybody's making money but the retail shareholder, is a very distinct possibility. The notion that 5.4 mil in loans has transpired to tens of millions of warrants being sold for as low as .50 on the dollar doesn't seem right in light of the dilution factor. I want the warrants to get washed out, but the benefit seems to be for a select few and I wonder why here and now in light of what has and is currently happening.

Since April 20th, we're traded roughly 45 million shares, so I'm hoping at least half of the 18 million that was left is already washed out considering the accelerated pace. Sorry to be late to the table on this and thanks again for everybody's patience with my posts. It's basically an issue of shareholder trust I'm questioning.

TIA

Share
New Message
Please login to post a reply